Importance of Melatonin in Assisted Reproductive Technology and Ovarian Aging

被引:160
|
作者
Tamura, Hiroshi [1 ]
Jozaki, Mai [1 ]
Tanabe, Manabu [2 ]
Shirafuta, Yuichiro [1 ]
Mihara, Yumiko [1 ]
Shinagawa, Masahiro [1 ]
Tamura, Isao [1 ]
Maekawa, Ryo [1 ]
Sato, Shun [1 ]
Taketani, Toshiaki [1 ]
Takasaki, Akihisa [2 ]
Reiter, Russel J. [3 ]
Sugino, Norihiro [1 ]
机构
[1] Yamaguchi Univ, Grad Sch Med, Dept Obstet & Gynecol, Minamikogushi 1-1-1, Ube, Yamaguchi 7558505, Japan
[2] Saiseikai Shimonoseki Gen Hosp, Dept Obstet & Gynecol, Yasuokacho 8-5-1, Shimonoseki, Yamaguchi 7596603, Japan
[3] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA
基金
日本学术振兴会;
关键词
melatonin; ovarian aging; reactive oxygen; oxidative stress; infertility; OXIDATIVE STRESS; DEVELOPMENTAL COMPETENCE; NEUROHORMONE MELATONIN; REACTIVE OXYGEN; IMPROVES; OOCYTE; QUALITY; WOMEN; METABOLISM; PROTECTION;
D O I
10.3390/ijms21031135
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melatonin is probably produced in all cells but is only secreted by the pineal gland. The pineal secretion of melatonin is determined by the light-dark cycle, and it is only released at night. Melatonin regulates biological rhythms via its receptors located in the suprachiasmatic nuclei of the hypothalamus. Melatonin also has strong antioxidant activities to scavenge free radicals such as reactive oxygen species (ROS). The direct free radical scavenging actions are receptor independent. ROS play an important role in reproductive function including in the ovulatory process. However, excessive ROS can also have an adverse effect on oocytes because of oxidative stress, thereby causing infertility. It is becoming clear that melatonin is located in the ovarian follicular fluid and in the oocytes themselves, which protects these cells from oxidative damage as well as having other beneficial actions in oocyte maturation, fertilization, and embryo development. Trials on humans have investigated the improvement of outcomes of assisted reproductive technology (ART), such as in vitro fertilization and embryo transfer (IVF-ET), by way of administering melatonin to patients suffering from infertility. In addition, clinical research has examined melatonin as an anti-aging molecule via its antioxidative actions, and its relationship with the aging diseases, e.g., Alzheimer's and Parkinson's disease, is also underway. Melatonin may also reduce ovarian aging, which is a major issue in assisted reproductive technology. This review explains the relationship between melatonin and human reproductive function, as well as the clinical applications expected to improve the outcomes of assisted reproductive technology such as IVF, while also discussing possibilities for melatonin in preventing ovarian aging.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] The importance of on-site genetic counseling for prospective assisted reproductive technology patients
    Benammar, Achraf
    Munnich, Arnold
    Poulain, Marine
    Magnan, Fanny
    Racowsky, Catherine
    Ayoubi, Jean-Marc
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2023, 40 (06) : 1341 - 1347
  • [42] Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes
    Christina E. Boots
    Micah J. Hill
    Eve C. Feinberg
    Ruth B. Lathi
    Susan A. Fowler
    Emily S. Jungheim
    Journal of Assisted Reproduction and Genetics, 2016, 33 : 647 - 656
  • [43] Pharmacogenetic algorithm for individualized controlled ovarian stimulation in assisted reproductive technology cycles
    Roque, Matheus
    Bianco, Bianca
    Christofolini, Denise M.
    Cordts, Emerson Barchi
    Vilarino, Fabia
    Carvalho, Waldemar
    Valle, Marcello
    Sampaio, Marcos
    Geber, Selmo
    Esteves, Sandro C.
    Barbosa, Caio Parente
    PANMINERVA MEDICA, 2019, 61 (01) : 76 - 81
  • [44] Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles
    van Wely, Madelon
    Kwan, Irene
    Burt, Anna L.
    Thomas, Jane
    Vail, Andy
    Van der Veen, Fulco
    Al-Inany, Hesham G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02):
  • [45] Comparison of ovarian responsiveness tests with outcome of assisted reproductive technology - a retrospective analysis
    Selcuk, Selcuk
    Bilgic, Bulent Emre
    Kilicci, Cetin
    Kucukbas, Mehmet
    Cam, Cetin
    Kutlu, Huseyin Tayfun
    Karateke, Ates
    ARCHIVES OF MEDICAL SCIENCE, 2018, 14 (04) : 851 - 859
  • [46] Long-term risk of ovarian tumours after assisted reproductive technology
    Spaan, M.
    Van den Belt-Dusebout, W.
    Lambalk, C. B.
    Van Boven, H. H.
    Burger, C. W.
    Van Leeuwen, F. E.
    HUMAN REPRODUCTION, 2019, 34 : 79 - 79
  • [47] Rs13405728 is associated with slow ovarian response in assisted reproductive technology
    Yin, Q-Q
    Zheng, J-H
    Hang, J.
    Cao, Y-J
    Zhang, B.
    Yang, D-Z
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (15) : 4757 - 4761
  • [48] The importance of on-site genetic counseling for prospective assisted reproductive technology patients
    Achraf Benammar
    Arnold Munnich
    Marine Poulain
    Fanny Magnan
    Catherine Racowsky
    Jean-Marc Ayoubi
    Journal of Assisted Reproduction and Genetics, 2023, 40 : 1341 - 1347
  • [49] The influences of weather on patients with different ovarian responses in the treatment of assisted reproductive technology
    Chang, SY
    Lan, KC
    Chen, CW
    Huang, FJ
    Tsai, MY
    Chang, CY
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2005, 22 (05) : 191 - 198
  • [50] Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes
    Boots, Christina E.
    Hill, Micah J.
    Feinberg, Eve C.
    Lathi, Ruth B.
    Fowler, Susan A.
    Jungheim, Emily S.
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2016, 33 (05) : 647 - 656